AR039272A1 - Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion - Google Patents
Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacionInfo
- Publication number
- AR039272A1 AR039272A1 ARP030101238A ARP030101238A AR039272A1 AR 039272 A1 AR039272 A1 AR 039272A1 AR P030101238 A ARP030101238 A AR P030101238A AR P030101238 A ARP030101238 A AR P030101238A AR 039272 A1 AR039272 A1 AR 039272A1
- Authority
- AR
- Argentina
- Prior art keywords
- glycyl
- group
- glycine
- liquid preparation
- peptide
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 6
- 239000007788 liquid Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 4
- -1 3-aminopropyloxy group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 150000004676 glycans Chemical class 0.000 abstract 3
- 229920001282 polysaccharide Polymers 0.000 abstract 3
- 239000005017 polysaccharide Substances 0.000 abstract 3
- GLUBLISJVJFHQS-SECBINFHSA-N 2-[[(2r)-2-azaniumyl-3-phenylpropanoyl]amino]acetate Chemical compound OC(=O)CNC(=O)[C@H](N)CC1=CC=CC=C1 GLUBLISJVJFHQS-SECBINFHSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 abstract 2
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- QMOQBVOBWVNSNO-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]acetyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(O)=O QMOQBVOBWVNSNO-UHFFFAOYSA-N 0.000 abstract 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- LESXFEZIFXFIQR-ZCFIWIBFSA-N D-Leu-Gly Chemical compound CC(C)C[C@@H]([NH3+])C(=O)NCC([O-])=O LESXFEZIFXFIQR-ZCFIWIBFSA-N 0.000 abstract 1
- 229920002307 Dextran Polymers 0.000 abstract 1
- 108010008488 Glycylglycine Proteins 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 abstract 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 abstract 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 abstract 1
- 229940043257 glycylglycine Drugs 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002112864 | 2002-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039272A1 true AR039272A1 (es) | 2005-02-16 |
Family
ID=29243336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101238A AR039272A1 (es) | 2002-04-16 | 2003-04-09 | Preparacion liquida que comprende un derivado de camptotecina y una composicion farmaceutica que puede producirse por liofilizacion de la preparacion |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050215485A1 (enExample) |
| EP (1) | EP1501549A2 (enExample) |
| JP (1) | JP3927954B2 (enExample) |
| KR (1) | KR100700963B1 (enExample) |
| CN (1) | CN100544769C (enExample) |
| AR (1) | AR039272A1 (enExample) |
| AU (1) | AU2003223120B2 (enExample) |
| BR (1) | BR0309283A (enExample) |
| CA (1) | CA2480425A1 (enExample) |
| HR (1) | HRP20040894A2 (enExample) |
| ME (1) | MEP31308A (enExample) |
| MX (1) | MXPA04010178A (enExample) |
| MY (1) | MY136696A (enExample) |
| NO (1) | NO20044964L (enExample) |
| PL (1) | PL371677A1 (enExample) |
| RS (1) | RS91204A (enExample) |
| RU (1) | RU2315623C2 (enExample) |
| TW (1) | TW200306314A (enExample) |
| UA (1) | UA77295C2 (enExample) |
| WO (1) | WO2003086471A2 (enExample) |
| ZA (1) | ZA200408008B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2556254A1 (en) * | 2004-02-13 | 2005-08-25 | Kabushiki Kaisha Yakult Honsha | Aqueous solution preparation containing camptothecins |
| CN1946421B (zh) | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
| NZ562951A (en) | 2005-07-14 | 2011-09-30 | Wellstat Biologics Corp | Cancer treatment using a Newcastle disease virus, a fluoropyrimidine and a camptothecin combination |
| JP2007260275A (ja) * | 2006-03-29 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びイオントフォレーシス投与用組成物 |
| CN102481352A (zh) | 2009-06-22 | 2012-05-30 | 惠氏有限责任公司 | 金黄色葡萄球菌抗原的免疫原性组合物 |
| SA114350400B1 (ar) | 2009-06-22 | 2016-05-26 | ويث ال ال سي | تركيبات وطرق لتحضير تركيبات مولدة للمناعة لمقترن بولي سكاريد كبسولي للنمط المصلي 5 و 8 من المكورات العنقودية الذهبية |
| CN102764260B (zh) * | 2011-04-30 | 2014-07-30 | 正大天晴药业集团股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
| US20140161876A1 (en) * | 2011-07-15 | 2014-06-12 | Konica Minolta, Inc. | Liposome-containing preparation utilizing dissolution aid, and method for producing same |
| WO2016103867A1 (ja) | 2014-12-26 | 2016-06-30 | 日本化薬株式会社 | カンプトテシン類高分子誘導体の医薬製剤 |
| CA2995053A1 (en) * | 2015-09-03 | 2017-03-09 | Nippon Kayaku Kabushiki Kaisha | Pharmaceutical composition containing camptothecin polymer derivative |
| CA2995029C (en) | 2015-09-25 | 2022-10-25 | Zy Therapeutics Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| WO2017150256A1 (ja) | 2016-03-01 | 2017-09-08 | 日本化薬株式会社 | カンプトテシン類高分子誘導体を含有する医薬製剤 |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
| WO2023095887A1 (ja) * | 2021-11-26 | 2023-06-01 | アステラス製薬株式会社 | インドシアニン化合物含有固形医薬組成物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
| ATE136898T1 (de) * | 1991-10-29 | 1996-05-15 | Glaxo Wellcome Inc | Wasserlösliche camptothecinderivate |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| RU2003100532A (ru) * | 2000-07-13 | 2004-07-20 | Дайити Фармасьютикал Ко., Лтд. (JP) | Фармацевтические композиции, содержащие соединение соединения dds |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
-
2003
- 2003-04-01 TW TW092107354A patent/TW200306314A/zh unknown
- 2003-04-09 AR ARP030101238A patent/AR039272A1/es unknown
- 2003-04-11 MY MYPI20031367A patent/MY136696A/en unknown
- 2003-04-15 RS YU91204A patent/RS91204A/sr unknown
- 2003-04-15 JP JP2003587152A patent/JP3927954B2/ja not_active Expired - Fee Related
- 2003-04-15 AU AU2003223120A patent/AU2003223120B2/en not_active Ceased
- 2003-04-15 EP EP03719110A patent/EP1501549A2/en not_active Withdrawn
- 2003-04-15 RU RU2004133349/15A patent/RU2315623C2/ru not_active IP Right Cessation
- 2003-04-15 CN CNB038082292A patent/CN100544769C/zh not_active Expired - Fee Related
- 2003-04-15 KR KR1020047016514A patent/KR100700963B1/ko not_active Expired - Fee Related
- 2003-04-15 CA CA002480425A patent/CA2480425A1/en not_active Abandoned
- 2003-04-15 PL PL03371677A patent/PL371677A1/xx not_active Application Discontinuation
- 2003-04-15 WO PCT/JP2003/004745 patent/WO2003086471A2/en not_active Ceased
- 2003-04-15 MX MXPA04010178A patent/MXPA04010178A/es active IP Right Grant
- 2003-04-15 US US10/509,912 patent/US20050215485A1/en not_active Abandoned
- 2003-04-15 BR BR0309283-6A patent/BR0309283A/pt not_active IP Right Cessation
- 2003-04-15 UA UA20041109367A patent/UA77295C2/uk unknown
- 2003-04-15 ME MEP-313/08A patent/MEP31308A/xx unknown
- 2003-04-15 HR HR20040894A patent/HRP20040894A2/xx not_active Application Discontinuation
-
2004
- 2004-10-05 ZA ZA200408008A patent/ZA200408008B/en unknown
- 2004-11-15 NO NO20044964A patent/NO20044964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200306314A (en) | 2003-11-16 |
| JP3927954B2 (ja) | 2007-06-13 |
| NO20044964L (no) | 2004-11-15 |
| MXPA04010178A (es) | 2005-06-08 |
| JP2005523329A (ja) | 2005-08-04 |
| AU2003223120B2 (en) | 2006-10-05 |
| PL371677A1 (en) | 2005-06-27 |
| BR0309283A (pt) | 2005-02-15 |
| RU2004133349A (ru) | 2005-05-27 |
| CN100544769C (zh) | 2009-09-30 |
| KR20050000516A (ko) | 2005-01-05 |
| WO2003086471A3 (en) | 2004-04-15 |
| US20050215485A1 (en) | 2005-09-29 |
| HRP20040894A2 (en) | 2005-10-31 |
| CN1646172A (zh) | 2005-07-27 |
| CA2480425A1 (en) | 2003-10-23 |
| MEP31308A (en) | 2010-10-10 |
| RU2315623C2 (ru) | 2008-01-27 |
| WO2003086471A2 (en) | 2003-10-23 |
| EP1501549A2 (en) | 2005-02-02 |
| AU2003223120A2 (en) | 2003-10-27 |
| AU2003223120A1 (en) | 2003-10-27 |
| MY136696A (en) | 2008-11-28 |
| ZA200408008B (en) | 2005-06-13 |
| KR100700963B1 (ko) | 2007-03-28 |
| RS91204A (sr) | 2006-12-15 |
| UA77295C2 (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2589921C (en) | Composition comprising a cyclodextrin and a proteasome inhibitor | |
| ATE178067T1 (de) | Camptothecinderivate | |
| MXPA01000601A (es) | Composicion farmaceutica estabilizada en forma liofilizada. | |
| PE84899A1 (es) | Formulaciones farmaceuticas que contienen voriconazol | |
| ATE252601T1 (de) | Lang wirkende insulinotrope peptide | |
| RU2001108569A (ru) | Стабилизированная фармацевтическая композиция в лиофилизированной форме | |
| DE60045524D1 (de) | Ein Huhn GnRH-II Analog zur Verwendung in der Reduktion des Tumorzellwachstums | |
| KR940008681A (ko) | 디클로페낙 염용 비경구 용액 | |
| KR970042553A (ko) | 캠프토테신 유도체 | |
| WO2001009163A3 (en) | Improvement of peptide transport by conjugation with bile acids | |
| RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
| ATE202931T1 (de) | Taxanderivate enthaltende arzneizubereitungen | |
| TR200103149T2 (tr) | Virüs ve mikoplazmanın korunması için yöntemler | |
| PT1589949E (pt) | Composições liofilizadas estabilizadas compreendendo inibidor da coagulação por factores tecidulares ou variante de inibidor da coagulação por factores tecidulares | |
| WO1990008557A1 (en) | Pharmaceutical formulations of plasminogen activator proteins | |
| IL83086A0 (en) | Stable,injectable solutions of vinca dimer salts | |
| RU2006126708A (ru) | Фармацевтическая композиция винфлунина, предназначенная для парентерального введения, способ получения и применения | |
| KR950024769A (ko) | 고농도 tcf 제제 | |
| DE69837159D1 (de) | Verfahren zur herstellung einer einzeldosisspritze mit lyophilisierter proteinmischung zur verabreichung eines volumens von weniger als 0,5 ml | |
| TW200505429A (en) | Pharmaceutical composition | |
| ES2167189A1 (es) | Formulacion farmaceutica estable para la administracion intravenosa o intramuscular, de principios activos peptidicos | |
| WO2004028457A3 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY | |
| RU2006115581A (ru) | Терапевтические композиции | |
| ATE83771T1 (de) | Aminochinolinderivate gegen malaria, verfahren zur herstellung und diese enthaltende pharmazeutische zusammensetzung. | |
| ATE121948T1 (de) | Stabilisierung von k1k2p pro. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |